HOXB7 and breast cancer: While some HOXB7 targets have been uncovered in Luminal and HER2+ molecular subtypes, little is known about the molecular pathways affected by HOXB7 overexpression in Triple-Negative BC (TNBC), which have cells lacking Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 expression.